个人简历

刘英，女，研究员，博士生导师。1961年10月出生，1999年3月毕业于日本国鸟取大学生命科学系生物化学专业，获得博士学位；自1999年5月至今在中国医学科学院基础医学研究所医学分子生物学国家重点实验室工作，2008年7月任副所院长。现任北京生化与分子生物学学会监事长、《中华医学遗传学杂志》编委，2015年荣获第七届“国家卫生计生有突出贡献中青年专家”称号。

研究领域

""1. 多基因疾病易感基因结构与功能的研究\r
\r
多基因疾病易感基因结构与功能的研究，以乙等重大疾病为主要研究对象，寻找、鉴定与疾病以及药物疗效相关的基因及遗传多态性位点，并在此基础上开展功能研究，以阐明疾病发生发展的分子机制，为肝细胞肝癌提供新的基于内质网应激信号通路的潜在靶点，为抗HBV治疗提供新的思路。\r
\r
2. 单基因疾病致病基因的识别及其功能研究\r
\r
通过基因突变筛查策略识别单基因遗传性神经系统疾病的致病基因，并研究致病基因突变体导致突触功能异常的分子机制。 """"

近期论文

1. Genetic Variation in STAT4 Predicts Response to Interferon-a Therapy for Hepatitis B e Antigen-Positive Chronic Hepatitis B\r
\r
HEPATOLOGY. 2016;63( 4):1102-1111\r
\r
2. PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling.\r
Int. J. Mol. Sci. 2015;16:9134-9151.\r
\r
3. . A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced.\r
Liver Int. 2014; 34: 1560–1565.\r
\r
4. A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations\r
Human Molecular Genetics, 2014;23(8):2210-2219\r
\r
5. A missense polymorphism in ATF6 gene is associated with susceptibility to hepatocellular carcinoma probably by altering ATF6 level\r
Int J Cancer.2014; 135:61–68\r
\r
6. Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity.\r
Int J Cancer. 2013;133(5):1085-93\r
\r
7. Replication of Genome Wide Association Studies on Hepatocellular Carcinoma Susceptibility Loci in a Chinese Population\r
PLoS ONE. 2013,8(10): e77315. doi:10.1371/journal.pone.0077315\r
\r
8. CD3Z Genetic Polymorphism in Immune Response to Hepatitis B Vaccination in Two Independent Chinese Populations\r
PLoS ONE. 2012, 7(4): e35303. doi:10.1371/journal.pone.0035303\r
\r
9. Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosis\r
J Med Genet. 2012;49:76-78\r
\r
10. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.\r
Antiviral Research. 2012;93(2):297-300\r
\r
11. Polymorphisms in ADAR1gene affect response to interferon alpha based therapy for chronic hepatitis B in Han Chinese\r
Antiviral Research. 2012;94: 272–275\r
\r
12. Human leukocyte antigen classI and classII genes polymorphisms might be associated with interferon therapy efficiency of chronic hepatitis B\r
Antiviral Research 2011;89:189–192\r
\r
13. Evaluation of Genetic Susceptibility Loci for Chronic Hepatitis B in Chinese: Two Independent Case-Control Studies\r
PLoS ONE. 2011, 6(3): e17608. doi:10.1371/journal.pone.0017608\r
\r
14. A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients.\r
Antiviral Research. 2009; 83(3):252-6\r
\r
15. Genetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetes.\r
Diabetes. 2008; 57(3): 777-82.